Medicare Price Negotiation Targeting Only Post-Exclusivity Drugs Proposed By Moderate House Democrats
Executive Summary
Legislation authorizing the US government to directly negotiate drug prices with manufacturers failed to pass in one key House committee as a trio of Democrats joined Republicans to vote against advancing the policy.
You may also be interested in...
Is There An ‘October Surprise’ Coming For Drug Pricing?
US Congressional Democrats made Halloween the new deadline for President Biden’s Build Back Better Act, to be passed through the reconciliation process. Savings generated from prescription drug price cuts represent a key pot of money to offset the legislation’s other spending initiatives.
Part B Is Plan B: Specialty Drug Prices Primed For Fallback Reform Effort
As Biden administration and MedPAC both work on ideas to overhaul Part B, marketers of physician-administered drugs (primarily for cancer, ophthalmology and rheumatological disorders) should prepare for a fight – but only if the broader ‘negotiation’ push fails.
Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.